Technology Networks covers findings that tie GLP-1 use to fewer deaths and hospital stays among people with fatty liver disease, known as MASLD.
Recap by typeshit. Full story at Technology Networks.
Lilly's pill had major heart events in 4.2% of patients vs 5.0% on insulin glargine. The Clinical Trial Vanguard argues rivals now need to show benefit, not just safety.
A Future Health & Medical Innovation panel weighs how much of the growing interest in peptides and exosomes is backed by evidence.
The aging doctor shares a headline saying new studies point to GLP-1 drugs slowing the biological clock, and notes himself that more research is needed.
An explainer on how GLP-1 drugs act on reward and craving in the brain, and the research testing them against alcohol, nicotine and other substance use.
Eligible workers get certain Type 2 diabetes GLP-1 drugs free as part of a benefits expansion covering more than 250 prescriptions, even as starter plan premiums rise.
Pipes argues some of these injectables are still in clinical trials yet already reach American buyers, and wants the FDA to target suppliers at the source.
Loading…